Article
Emerging drugs for the treatment of gastrointestinal stromal tumour.
Expert opinion on emerging drugs - 1 Dec 2017
Kasireddy Vineela, von Mehren Margaret
Abstract excerpt
INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have transformed the treatment landscape for patients with gastrointestinal stromal tumors (GIST). Unfortunately, resistance to the currently approved TKIs poses a huge challenge, and patients are in need of additional therapeutic options. Fortunately, many novel therapeutic approaches are being tested in treatment of GIST to overcome resistance to the approved TKIs...
Topics
Join the communities discussing this publication.